Sizzling Stock Picks

[Stock Rockstar]

$TWSI Begins Medical Wound Care Product Sales into China
By: staff reporter, John Bodger
Last Updated: April 21, 2015 12:58 PM EST

(NEW YORK)--TriStar Wellness Solutions, Inc. (OTCQB: TWSI) a leading developer and marketer of advanced wound care products, recently announced that through their subsidiary, HemCon Medical Technologies, Inc they had received regulatory approval from the China Food and Drug Administration (CFDA) to sell their medical products into China.

TWSI announced it had commercially entered the Chinese market this month by accepting an order through a distributor on the mainland. HemCon's launch into the Chinese market includes their full portfolio of wound care solutions, which are protected by patents both in China and throughout the world, and now positions them in the wound care market in China which is estimated at $1.2 billion.
HemCon has prior experience in the pan-Asian market having successfully established a wound care product line in Japan with their partner ZERIA Pharmaceutical.

Michael Wax, President and CEO commented in a recent press release, "With our initial Chinese order in hand, combined with the Chinese government's approval for import of our dressings, we are looking ahead to building a robust business in a rapidly growing market. We have expectations to participate in the fast growing pan-Asian health care industry and specifically the increasing demand for wound care in China."

TWSI currently traded on the OTCQB exchange, and has only around 24 million shares issued and outstanding. Based on their growing US and military sales, low shares outstanding, and now entry into the Chinese medical product market, TWSI stock has real potential to make a run back to $1.00 a share again.

TWSI current stock quote
http://www.otcmarkets.com/stock/twsi/quote

About HemCon Medical Technologies, Inc.

HemCon Medical Technologies Inc., founded in 2001, develops, manufactures, and markets innovative technologies for hemostatic devices for the control of bleeding resulting from trauma or surgery. HemCon products are designed for use by military and civilian first responders as well as medical professionals in hospital and clinical settings where control of bleeding are of critical importance. HemCon is headquartered in Portland, Ore. With a 36,000 sq. ft. state of the art manufacturing facility, the Company has additional commercial operations in Ireland and the Czech Republic. For more information, please visit www.hemcon.com

Full article and website:
www.wallstreetnewscast.com/news/2015/04/twsi-china-1842.html